The new era of treatments for kidney transplant recipients.

Despite substantial improvements in short-term outcomes after kidney transplantation, important unmet clinical needs persist. These include expanding transplant access for highly sensitized candidates, mitigating the short- and long-term consequences of ischemia-reperfusion injury, preventing acute rejection while preserving allograft function, minimizing off-target toxicities associated with calcineurin inhibitor-based immunosuppressive regimens, improving adherence to long-term immunosuppressive therapy, and developing effective treatments for late antibody-mediated rejection. A growing pipeline of novel therapeutic agents aims to address these challenges by targeting key immunologic and injury pathways that contribute to allograft dysfunction and failure. In this review, we examine emerging pharmacologic strategies currently undergoing clinical evaluation in these domains and critically assess their potential to improve long-term graft survival and patient outcomes. We also discuss the key considerations and priorities that should inform future clinical investigation in kidney transplantation.